Medtronic's unchanged annual outlook clouds upbeat quarterly results
FILE PHOTO: A general view of the logo of Medtronic, a healthcare technology and pharmaceutical company, at their plant, in Galway, Ireland, April 11, 2025. REUTERS/Clodagh Kilcoyne/File Photo
By Padmanabhan Ananthan and Puyaan Singh
Feb 17 (Reuters) - Medtronic surpassed Wall Street expectations for third-quarter profit and revenue on Tuesday, driven by strong demand for its heart devices, but its shares fell 2.6% after the company left its forecast for full-year adjusted profit unchanged.
Medtech firms have been riding a wave of increased adoption of newer technologies and a rebound in surgeries.
The forecast being maintained despite the quarterly beat implies fourth-quarter growth will slow, said Bernstein analyst Christian Moore.
Medtronic's finance chief, Thierry Pieton, told Reuters that although the company expects 6% revenue growth for the fourth quarter, extra tax costs will hurt some of the profit upside.
Medtronic expects an about $300 million hit from tariffs in fiscal 2027, up from around $185 million in fiscal 2026. It maintained its fiscal 2026 adjusted per share profit forecast at $5.62 to $5.66.
The company also faces fresh attention on its patient monitoring business after life sciences firm Danaher struck a $9.9 billion deal to buy rival Masimo on Tuesday.
Medtronic's acute monitoring segment houses its pulse-oximetry systems and operates a duopoly with Masimo.
Medtronic CEO Geoff Martha told Reuters that while Masimo's integration could create disruptions for Danaher, the deal is unlikely to change long-term competitive dynamics in the patient-monitoring market.
Sales in Medtronic's cardiovascular segment jumped 13.8% to $3.46 billion during the quarter, powered by strong demand for its pulsed field ablation (PFA) portfolio.
Although Medtronic's worldwide cardiac ablation heart device sales rose 80% in the quarter, including PFA, the growth missed buyside expectations, feeding a narrative that the PFA market has slowed in the last few months, said Moore.
Third-quarter revenue was $9.02 billion, beating analysts' average estimate of $8.91 billion, according to data compiled by LSEG.
Medtronic reported quarterly adjusted profit of $1.36 per share, above estimates of $1.33 per share.
(Reporting by Padmanabhan Ananthan and Puyaan Singh in Bengaluru; Editing by Sahal Muhammed)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- US equity funds record nine-month high outflows as oil stokes inflation fears
- Jefferies backs SPIE on growth recovery, upgrades Adecco as estimates improve
- Medtronic, Inc. (MDT) PT Raised to $105 at Bernstein SocGen Group
Create E-mail Alert Related Categories
General News, ReutersRelated Entities
Sanford C. BernsteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share